The expression of PD-1 and its ligands increases in Leishmania infection and its blockade reduces the parasite burden

被引:16
|
作者
Jafarzadeh, Abdollah [1 ,2 ]
Kumar, Sunil [3 ]
Bodhale, Neelam [3 ]
Jafarzadeh, Sara [4 ]
Nemati, Maryam [2 ,5 ]
Sharifi, Iraj [6 ]
Sarkar, Arup [7 ]
Saha, Bhaskar [3 ,4 ,7 ]
机构
[1] Kerman Univ Med Sci, Sch Med, Dept Immunol, Kerman, Iran
[2] Rafsanjan Univ Med Sci, Res Inst Basic Med Sci, Mol Med Res Ctr, Rafsanjan, Iran
[3] Natl Ctr Cell Sci, Pune 411007, India
[4] Kerman Univ Med Sci, Student Res Comm, Sch Med, Kerman, Iran
[5] Kerman Univ Med Sci, Sch Para Med, Dept Haematol & Lab Sci, Kerman, Iran
[6] Kerman Univ Med Sci, Leishmaniasis Res Ctr, Kerman, Iran
[7] Trident Acad Creat Technol, Bhubaneswar, India
关键词
Leishmaniasis; Immune responses; Programmed death-1; PD-L1; PD-L2; T cell exhaustion; T-CELL EXHAUSTION; IFN-GAMMA; TGF-BETA; POSTTRANSLATIONAL MODIFICATIONS; VISCERAL LEISHMANIASIS; PROGRAMMED DEATH-1; IMMUNE-RESPONSE; DENDRITIC CELLS; RECEPTOR; CD8(+);
D O I
10.1016/j.cyto.2022.155839
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The expression of programmed cell death protein-1 (PD-1) and its ligands-PD-L1 and PD -L2-on T cells and macrophages', respectively, increases in Leishmania infection. The PD-1/PD-L1 interaction induces T cell anergy, T cell apoptosis and exhaustion, diversion of T cells toward TH2 and T-reg cells but inhibits M1 macrophage activities by suppression of nitric oxide (NO) and reactive oxygen species (ROS) production. These changes exacerbate Leishmania infection. As PD-L1-deficient, but not PD-L2-deficient, mice were protected against L. mexicana infection, differential roles have been proposed for PD-L1 and PD-L2 in mouse models of leishmaniasis. Blockade of PD-1/PD-L1 interaction in various in vitro and Leishmania-infected mouse, hamster and dog models enhanced IFN-gamma and NO production, reduced IL-10 and TGF-8 generation, promoted T cell proliferation and reduced parasite burden. Therefore, PD-1/PD-L1 blockade is being considered as a potential therapeutic strategy to restore protective immunity during leishmaniasis, particularly, in drug-resistant cases.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Expression of PD-1 and Its Ligands in Human Malignant Pleural Mesothelioma
    Marcq, Elly
    De Waele, Jorrit
    Van Audenaerde, Jonas
    Zwaenepoel, Karen
    Baas, Paul
    Pauwels, Patrick
    Smits, Evelien L. J.
    Van Meerbeeck, Jan P.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S351 - S351
  • [2] PD-1 and its ligands in tolerance and immunity
    Keir, Mary E.
    Butte, Manish J.
    Freeman, Gordon J.
    Sharpel, Arlene H.
    ANNUAL REVIEW OF IMMUNOLOGY, 2008, 26 : 677 - 704
  • [3] Class I HDAC inhibition upregulates PD-1 ligands in melanoma and increases the efficacy of PD-1 blockade
    Woods, David M.
    Sodre, Andressa L.
    Sarnaik, Amod
    Sotomayor, Eduardo M.
    Weber, Jeffrey
    CANCER RESEARCH, 2015, 75
  • [4] Characteristic expression of PD-1 and its ligands mRNAs in patients with noninfectious uveitis
    Meng, Qianli
    Yang, Peizeng
    Guo, Haike
    Zhang, Liang
    Chen, Xuan
    Jiang, Zhengxuan
    Hou, Shengping
    Fang, Mengyuan
    Cui, Ying
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (01): : 323 - 329
  • [5] Expression of programmed death-1 (PD-1) and its ligands in Sezary syndrome
    Saulite, Ieva
    Ignatova, Desislava
    Chang, Yun-Tsan
    Fassnacht, Christina
    Varypataki, Eleni
    Anzengruber, Florian
    Nageli, Mirjam
    Cozzio, Antonio
    Dummer, Reinhard
    Scarisbrick, Julia
    Pascolo, Steve
    Hoetzenecker, Wolfram
    Bobrowicz, Malgorzata
    Guenova, Emmanuella
    EUROPEAN JOURNAL OF CANCER, 2019, 119 : S13 - S13
  • [6] Differential regulation of PD-1 and its ligands in allergic asthma
    Bratke, K.
    Fritz, L.
    Nokodian, F.
    Geissler, K.
    Garbe, K.
    Lommatzsch, M.
    Virchow, J. C.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2017, 47 (11): : 1417 - 1425
  • [7] PD-1 and its ligands are important immune checkpoints in cancer
    Dong, Yinan
    Sun, Qian
    Zhang, Xinwei
    ONCOTARGET, 2017, 8 (02) : 2171 - 2186
  • [8] The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies
    Marinelli, Oliviero
    Annibali, Daniela
    Aguzzi, Cristina
    Tuyaerts, Sandra
    Amant, Frederic
    Morelli, Maria Beatrice
    Santoni, Giorgio
    Amantini, Consuelo
    Maggi, Federica
    Nabissi, Massimo
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [9] PD-1 and its ligands in T-cell immunity
    Keir, Mary E.
    Francisco, Loise M.
    Sharpe, Arlene H.
    CURRENT OPINION IN IMMUNOLOGY, 2007, 19 (03) : 309 - 314
  • [10] HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
    Woods, David M.
    Sodre, Andressa L.
    Villagra, Alejandro
    Sarnaik, Amod
    Sotomayor, Eduardo M.
    Weber, Jeffrey
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (12) : 1375 - 1385